Mark S. Roh - Concepedia

Author

Mark S. Roh

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

M Roh, M S Roh, M. Roh, M. S. Roh, M.S Roh, M.S. Roh, MARK S. ROH, Mark Roh, Mark S Roh, Mark S. ROH

264

Publications

6.5K

Citations

H-Index

127

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Agricultural Research Service Allegheny General Hospital NSABP Foundation U.S. National Arboretum

About

Mark S. Roh is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and surgical oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	38	2.7K
2	Natural Sciences	14	20	355
3	Health Sciences	12	13	281
4	Engineering	9	9	183
5	Management	1	1	15

Mark S. Roh

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03 Mark S. Roh, Linda H. Colangelo, Michael J. O’Connell, Journal of Clinical Oncology	2009	935
Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04 Michael J. O’Connell, Linda H. Colangelo, Robert W. Beart, Journal of Clinical Oncology	2014	438
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. Mark S. Talamonti, Mark S. Roh, S. Curley, Journal of Clinical Investigation Tyrosine KinaseGastroenterologyPathologyCancer BiologyTumor Biology	1993	397
Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies A. Scott Pearson, Francesco Izzo, R.Y.Declan Fleming, The American Journal of Surgery Surgical OncologyHepatologyMedicineHepatobiliary TumorInterventional Radiology	1999	370
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial Carmen J. Allegra, Greg Yothers, Michael J. O’Connell, JNCI Journal of the National Cancer Institute	2015	326
OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer Graeme J. Poston, René Adam, Steven R. Alberts, Journal of Clinical Oncology	2005	262
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer Hyuk-Chan Kwon, Mark S. Roh, Sung Yong Oh, Annals of Oncology Gastrointestinal OncologyAdvanced Gastric CancerMedicinePrognostic Value5-Fluorouracil/oxaliplatin Chemotherapy	2007	198
The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Mark S. Roh, Greg Yothers, M J O'Connell, Journal of Clinical Oncology Surgical OncologyPreoperative Multimodality TreatmentOral CapecitabineNsabp R-04Cancer Management	2011	194
Long-term Survival After An Aggressive Surgical Approach in Patients With Breast Cancer Hepatic Metastases Georges Vlastos, David L. Smith, S. Eva Singletary, Annals of Surgical Oncology Surgical OncologyBreast OncologyHepatologyMedicineHepatobiliary Tumor	2004	174
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy Jaffer A. Ajani, David M. Ota, J. Milburn Jessup, Cancer Surgical OncologyLocoregional Gastric CarcinomaMicroscopic CarcinomaGastrointestinal OncologyMedicine	1991	168

Page 1